This aligns with the scientific literature, indicating that AD patients tend to show more neuropsychiatric symptoms, including anxiety, depression, agitation, apathy, or sleep disturbances, due to the proliferation of amyloid plaques and phosphorylated tau protein, and the reduction in the hippocampal volume [42,44,45]. Here, MAPT is linked to depressive symptom measurement.